Table 4.
Family History of Cancer and Endometrial Cancer Risk by Microsatellite Instability (MSI), 2002-2006, Alberta, Canada.
| Cases | ||||||
|---|---|---|---|---|---|---|
| Controls (n=1015) |
MSI +a(n=129) | MSI - a(n=330) | P | |||
| N | ORb (95% CI) | N | ORb (95% CI) | valuec | ||
| First degree family history of cancer | ||||||
| Uterine | 44 | 8 | 1.5 (0.7, 3.3) | 18 | 1.3 (0.8, 2.4) | 0.84 |
| Colorectal | 105 | 20 | 1.4 (0.8,2.5) | 31 | 0.9 (0.6, 1.4) | 0.14 |
| UCca | 143 | 27 | 1.5 (0.9, 2.5) | 48 | 1.1 (0.7, 1.5) | 0.19 |
| Lung | 105 | 13 | 0.9(0.5, 1.7) | 32 | 0.9 (0.6, 1.4) | 0.99 |
| First and second degree family history of cancer | ||||||
| Uterine | 95 | 16 | 1.4(0.8, 2.5) | 39 | 1.4(0.9, 2.1) | 0.94 |
| Colorectal | 251 | 41 | 1.4(1.0, 2.2) | 78 | 1.0 (0.7, 1.3) | 0.09 |
| UCca | 318 | 54 | 1.6(1.1, 2.4) | 104 | 1.0(0.8, 1.4) | 0.05 |
| Lung | 252 | 33 | 1.0 (0.7, 1.6) | 80 | 0.9 (0.7, 1.3) | 0.81 |
OR, odds ratio; CI, confidence interval; UCca, uterine or colorectal cancer or both.
MSI + includes cases with two or more markers with instability; MSI- includes cases with either one or zero markers with instability
Adjusted for age (<40, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79), residence, BMI (<24.9, 25-29.9, ≥30, unknown), parity (0, 1-2, ≥3), oral contraception use (never, 6-59, ≥60 months, unknown), number of first degree relatives or number of first and second degree relatives (continuous) and menopausal status/hormone therapy (premenopausal, peri/postmenopausal without HT, peri/postmenopausal with CCE+P, peri/postmenopausal with other combinations, unknown
Comparing the OR for MSI+ with MSI- cancer